Structural differences between dengue viruses circulating in humans and viruses used for vaccine research by Raut, R. & De Silva, A.M.
Structural differences between dengue
viruses circulating in humans and viruses
used for vaccine research
Rajendra Raut*,1 & Aravinda M de Silva1
1Department of Microbiology & Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
*Author for correspondence: rajendra raut@med.unc.edu
“By using fully mature infectious stocks of low passage, contemporary clinical strains each DENV
serotype, the PRNT can be developed into a better tool for evaluating vaccine responses”
First draft submitted: 10 May 2019; Accepted for publication: 21 May 2019; Published online:
8 July 2019
Keywords: cell culture • dengue virus • maturation • neutralization • Sri Lanka • vaccine-prophylactic
Four dengue virus (DENV) serotypes are mosquito-borne flaviviruses of humans. The main mosquito vector of
DENV, Aedes aegypti, is difficult to control because urbanization and other human activities create environments
that strongly favor this species. Given the challenges of mosquito vector control and the absence of other effective
countermeasures, DENVs are thriving and infect several hundred million individuals, living in tropical and
subtropical regions of the world [1,2]. Highly effective vaccines have been developed against related flaviviruses such
as yellow fever (YFV), Japanese encephalitis (JEV) and tick-borne encephalitis (TBE) viruses [3]. The development
of DENV vaccines is more challenging because of the presence of four serotypes and the possibility of inadequate
immunity enhancing the replication of DENVs and thus, increasing the risk of severe disease [3]. Three live
attenuated tetravalent DENV vaccines are at different stages of testing in people. Most recently, the public health
community and vaccine developers faced a major setback when the leading candidate, Dengvaxia, was discovered
to have a safety signal in some children [4]. Furthermore, we recently discovered that dengue serotype 1 viruses
(DENV1) widely used for laboratory research are structurally different from DENV1 viruses circulating in the
plasma of those infected [5]. Here, we discuss our findings and the implications for DENV research and vaccines.
Starting in the 1960s, cell culture-based viral plaque reduction neutralization tests (PRNT) have been used as
a gold standard to detect human antibodies correlated with protective immunity to flaviviruses. A PRNT50 titer
(serum dilution neutralizing 50% of infectious virus) equal to or greater than 1:10 has been established clinically
as protective for YFV and JEV [6,7]. Although a PRNT50 threshold titer has not been established for each DENV
serotype, regulatory agencies and vaccine developers have relied on the presence of neutralizing antibodies to
guide the development of DENV vaccines [8]. However in dengue vaccine clinical trials, many individuals with
neutralizing antibodies were not protected indicating that, unlike in the case of JEV and YFV, the mere presence of
neutralizing antibodies was not sufficient for protection from DENVs [9]. As described next, structural differences
between DENVs produced in the laboratory and DENVs circulating in people, may explain why some people who
received DENV vaccines experienced breakthrough infections despite developing neutralizing antibodies.
Maturation state of DENV circulating in people
DENVs contain two integral membrane proteins, envelope (E) and premembrane (prM), which are embedded
within the lipid bilayer derived from host cell endoplasmic reticulum during virion assembly. As assembled immature
virions move through the secretory pathway, PrM protein is cleaved by a host furin protease in the trans-Golgi
network. The cleavage of prM leads to the rearrangement of E proteins to form mature infectious virions, which
are released from infected cells. It has been widely recognized that prM processing is inefficient in cell lines widely
used to produce laboratory stocks of DENVs. DENVs produced in laboratories are a heterogeneous mixture of
immature, partially mature and fully mature virions containing variable amounts of prM [10]. Using conventional
assays, it has been challenging to determine the structure, composition and maturation state of DENVs circulating
in people because of the transient, low viremia and the large excess of other plasma proteins.
Recently, we characterized the maturation state of DENV1 in human plasma using samples from an epidemic
in Sri Lanka and a novel immunocapture assay to detect virions with unprocessed prM protein on their surface [5].
For this study, we only used blood samples from people experiencing primary infections collected before the
development of specific antibodies (first 4 days of symptoms), which are likely to interfere with our assays. We
observed that DENV1 in the plasma of infected patients had very low or no detectable prM protein on the surface
indicating that the virions were fully mature. In contrast, when the same plasma DENVs were passaged once or
twice in mammalian or insect laboratory cell lines, most virions released from the cells contained prM protein on
the surface indicating incomplete processing and maturation. Laboratory cell lines selected for growing DENVs
support robust viral replication. It is likely that the high concentration of intracellular virions overwhelms the host
furin protease in the trans-Golgi apparatus that cleaves prM to generate mature virions. In support of this model,
we observed that Vero cells engineered to overexpress furin released DENV1 that were more mature than DENV1
released from regular Vero cells [5].
Our studies also demonstrated that plasma DENV1 had a 10- to 100-fold greater specific infectivity compared
with DENV1 clinical and laboratory strains produced using laboratory cell lines. The difference in specific infectivity
could not be completely attributed to the differences in maturation state indicating there are other structural and
biochemical differences between plasma and cell culture viruses beyond maturation state.
Implications for vaccine development
The PRNT, which utilizes cell lines and laboratory produced stocks of DENVs, has been a workhorse for measuring
neutralizing antibody and for guiding the development of dengue vaccines. We performed PRNTs to compare
the ability of human antibodies to neutralize human plasma and cell culture-derived DENV1. DENV1 serotype
specific human monoclonal antibodies (mAbs) and homotypic immune sera from people exposed to primary
DENV1 infections were effective at neutralizing both plasma and cell culture produced DENV1 [5]. DENV
serotype cross-reactive human monoclonal antibodies (mAbs) and heterotypic immune sera from people exposed to
primary DENV2 or DENV3 infections efficiently neutralized cell culture produced DENV1 and poorly neutralized
or failed to neutralize human plasma derived DENV1. Other studies have also demonstrated that DENVs released
from primary human cells [11] and mature DENV from furin overexpressing cells [12,13] are resistant to neutralization
by some cross-reactive antibodies compared with immature virions produced using standard cell lines. Most human
DENV serotype-cross reactive antibodies target conserved epitopes at or near the fusion loop at the tip of domain
II of E protein. This region of E protein is partially exposed and accessible to antibody binding in immature virions
with unprocessed prM, whereas in mature virions the fusion loop is buried and not readily accessible to antibody
binding [14]. Our findings suggest that the current PRNT utilizing partially mature DENV stocks will overestimate
the levels of DENV neutralizing antibodies induced by vaccines. Indeed, many people who received a leading
dengue vaccine candidate experienced breakthrough infections despite having relatively high PRNT50 titers after
vaccination [9]. We need to re-examine ways of growing DENVs in cell culture to better reflect the properties of
viruses circulating in people. By using fully mature infectious stocks of low passage, contemporary clinical strains
each DENV serotype, the PRNT can be developed into a better tool for evaluating vaccine responses.
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